A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.
PHASE3CompletedINTERVENTIONAL
Enrollment
188
Participants
Timeline
Start Date
September 30, 2005
Primary Completion Date
March 31, 2007
Study Completion Date
March 31, 2007
Conditions
Schizophrenia
Interventions
DRUG
Risperidone long-acting injectable
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00843687 - A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients. | Biotech Hunter | Biotech Hunter